JPMorgan Chase & Co. Reaffirms “Neutral” Rating for AstraZeneca plc (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating reaffirmed by stock analysts at JPMorgan Chase & Co. in a note issued to investors on Monday.
Several other equities research analysts have also recently weighed in on the stock. Shore Capital restated a “hold” rating on shares of AstraZeneca plc in a research report on Friday. Credit Suisse Group AG restated an “underperform” rating and issued a GBX 4,000 ($52.21) price target on shares of AstraZeneca plc in a research report on Friday. Citigroup Inc. restated a “buy” rating and issued a GBX 6,000 ($78.32) price target on shares of AstraZeneca plc in a research report on Wednesday, October 5th. Deutsche Bank AG restated a “buy” rating and issued a GBX 5,800 ($75.71) price target on shares of AstraZeneca plc in a research report on Wednesday, October 5th. Finally, Bryan, Garnier & Co reduced their price target on shares of AstraZeneca plc from GBX 5,400 ($70.49) to GBX 5,220 ($68.14) and set a “buy” rating on the stock in a research report on Tuesday, October 4th. Five equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. AstraZeneca plc has a consensus rating of “Hold” and an average price target of GBX 4,937.91 ($64.46).
AstraZeneca plc (LON:AZN) traded up 0.20% during midday trading on Monday, hitting GBX 5096.00. 1,850,620 shares of the stock traded hands. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00. The company’s market cap is GBX 64.46 billion. The firm’s 50-day moving average is GBX 5,005.11 and its 200-day moving average is GBX 4,435.88.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/10/jpmorgan-chase-co-reaffirms-neutral-rating-for-astrazeneca-plc-azn.html
The company also recently disclosed a dividend, which was paid on Monday, September 12th. Stockholders of record on Thursday, August 11th were paid a dividend of GBX 68.70 ($0.90) per share. The ex-dividend date of this dividend was Thursday, August 11th. This represents a dividend yield of 1.37%.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.